← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-10 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
CGTBiologicstaleShanghai Cell Therapy Group Co.…Phase 2

Anti-mesothelin chimeric T cell receptor (CAR, Anti-mesothelin chimeric T cell receptor, Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL))

Cervical Cancer; Pancreatic Cancer · Cervical Cancer

#CervicalCancer#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleAlbert Einstein College of Medi…Phase 1

Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes (Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes)

HLA-A2 Positive Cells Present; Metastatic Malignant Neoplasm · HLA-A2 Positive Cells Present

#HLA-A2PositiveCellsPresent#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleAcademy Military Medical Scienc…Preclinical

Antibiotic selection based on the antibiotic susceptibility testing (Antibiotic selection based on the antibiotic susceptibility testing)

Gastritis; Gastric Ulcer · Gastritis

#Gastritis#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicShenzhen Geno-Immune Medical In…Phase 2

Antigen-specific CAR T, CTL and DCvac to treat melanoma. (Antigen-specific CAR T, CTL and DCvac to treat melanoma.)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
ADCBiologicstaleCentral South UniversityPreclinical

Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate (Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate)

Sepsis (SMQ); Opportunistic Infections · Sepsis (SMQ)

#SepsisSMQ#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
AntibodystaleAbbViePreclinical

adalimumab (Humira, Application of Adalimumab)

Crohn's Disease · Crohn's Disease

#CrohnsDisease#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

Aribulin;carboplatin;bevacizumab (Aribulin;carboplatin;bevacizumab)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodyInstitut BergoniéPhase 2

atezolizumab (Tecentriq, Association atezolizumab + BDB001 + RT)

Solid Tumor, Adult; Pancreatic Cancer · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 RECRUITING
AntibodystaleInstitut BergoniéPhase 2

durvalumab (Imfinzi, Association of lurbinectedin and durvalumab)

Small Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodyInstitut BergoniéPhase 2

pembrolizumab (Keytruda, Association of pembrolizumab + cabozantinib)

Soft Tissue Sarcoma Adult; Advanced Soft-tissue Sarcoma · Soft Tissue Sarcoma Adult

#SoftTissueSarcomaAdult#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleMerck KGaA, Darmstadt, GermanyPhase 2

Atacicept (Atacicept)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ])

Lymphoma, Follicular · Lymphoma, Follicular

#LymphomaFollicular#Antibody#Phase2#항체#면역항체+4
효능 ORR 87.5%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

adjuvant (Atezolizumab, Atezolizumab (adjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 15.4%임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

neoadjuvant (Atezolizumab, Atezolizumab (neoadjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 91.2%임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + Ipatasertib)

Gastric Adenocarcinoma; Metastatic Gastric Cancer · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + RP1)

Triple Negative Breast Neoplasms · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab Cohort 7)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase2#항체#면역항체+2
효능 ORR 20%임상시험 1상태 ACTIVE
CGTBiologicstaleRochePhase 1

atezolizumab (Tecentriq, Atezolizumab and Interleukin-12 Gene Therapy)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 DISCONTINUED
AntibodyRochePhase 2

atezolizumab (Tecentriq, Atezolizumab combined with bevacizumab combined with β- alanine)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab, 6-mercaptopurine, 6-thioguanine)

Solid Tumor, Adult; Metastatic Cancer · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE

86 / 209 페이지

← 이전다음 →